Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

Return to program book search

Session Information

FRM F110 - Diagnostically Challenging Melanocytic Lesions: Integration of Ancillary Studies with Morphologic and Clinical Findings

Open admission to eligible categories, no tuition or ticket


Date: Monday, March 04

CME Credits: 2.00

Location: Room B116/117

Time: 10:00 AM - 12:00 PM

Director: Klaus J. Busam, MD


  • Pedram Gerami, MD, FAAD
  • Timothy H. McCalmont, MD
  • Iwei Yeh, MD, PhD, FAAD

Learning Objectives:
Following this course, the attendee should be able to:

  • Describe the principles of comparative genomic hybridization and fluorescence in situ hybridization for diagnosis of melanocytic lesions
  • Discuss the indications, sensitivity and specificity of the tests
  • Recognize pitfalls in the performance and utilization of FISH and CGH

The session will review the use of modern ancillary tests for improved accuracy of the diagnosis of melanocytic proliferations. The principles and clinical applications of cytogenetic studies (fluorescence in situ hybridization, array comparative genomic hybridization), immunohistochemical tests and mutational analysis as relevant for the diagnosis of melanocytic lesions will be discussed. Test indications and current data on sensitivity and specificity will be presented with emphasis on the need for clinical and pathologic correlation. Pearls and pitfalls will be illustrated on individual cases, addressing issues such as the diagnosis of spitzoid melanoma, blue nevus-like melanoma, nevoid and desmoplastic melanoma.


Monday, March 04
10:00 AMComparative genomic hybridization of melanocytic tumors / Dr. Yeh
10:30 AMFISH analysis for the diagnosis of melanocytic tumors / Dr. Gerami
11:00 AMThe UCSF experience using CGH and FISH for the diagnosis of melanocytic tumors / Dr. McCalmont
11:30 AMThe MSKCC experience in using ancillary studies for the diagnosis of problematic melanocytic tumors / Dr. Busam